Institute of Molecular Genetics of the Czech Academy of Sciences
We transfer the research results of the Institute of Molecular Genetics into practice. In the Centre of Technology Transfer (CTT), we connect researchers with the commercial sphere and supervise the use of the procedures and technologies developed by us under fair conditions.
Services for researchers:
intellectual property (IP) consultancy,
assistance with the notification of creation of a research tool or submitting a patent application,
finding a suitable commercial partner,
negotiation, administrative and legislative support.
Services for commercial organisations:
liaison with the inventor of the discovery,
market research with regard to the commercial potential of the technology,
securing a licence,
assistance with setting up a spin-off company.
Contact the Centre of Technology Transfer
Send us an e-mail to email@example.com or call us on +420 29644 3199, +420 777 468 683
Frequently asked questions
Why should I announce creation of a result?
IMG employees should announce the result whenever they believe that it could be used in practice in the future. Research results are usually in the very early stages of development and require significant investment before being launched on the market. The intellectual property protection following the Nofitication of Research result (invention) disclosure may be an incentive for commercial partners to make such an investment.
When and how can I announce creation of a research tool?
These are usually results such as antibodies, vectors, plasmids, cell lines, mice, and others used as “tools” in the research process. Research tools do not necessarily have to be protected by patents to be licensed to commercial third parties and to generate revenue for your laboratory. Additional research tools (such as new separation processes) may need to be patented for a company to invest in technical development to make the process widely applicable. If you possess research tools that you think are valuable, IMG will work with you to develop their appropriate protection, licensing and distribution strategy. We will also help you to distribute research materials at zero or minimal cost to other academic collaborators while maintaining the business potential of the materials.
Should I announce software as well?
Yes, software code licensing is possible based on various distribution strategies, for commercial development and distribution for non-commercial and / or academic purposes, etc., and can be practically usable and commercially successful. If you have software that you believe involves a patentable process, you should submit the Nofitication of Research result (invention) disclosure for the patentable process and submit the IMG software code.
Should I report contributions from inventors other than IMG?
All contributors to ideas leading to the invention should be listed in your Nofitication of Research result (invention) disclosure, even if they are not IMG employees. The CTT, together with a legal adviser, will determine the rights of these persons and institutions. It is sensible to discuss collaborations (preferably before they begin) with CTT to understand the implications for any subsequent inventions.
What are the rights of a research sponsor to discoveries related to my research?
The rights granted to research sponsors vary according to the contract concluded. See the Internal Intellectual Property Directive for more information.
What is considered a disclosure of the invention?
Everything that is easily accessible to the public (diary, conference presentations, publications on the web, Facebook, video on YouTube, even dissertations indexed in the library) and describes in sufficient detail the basic ideas that someone else would be able to create and use as invention; i.e., those ideas that are new.
The Institute of Molecular Genetics of the Czech Academy of Sciences is investigator of project TP01010060 “Applied Molecular Genetics and Biology – IMG Gamma 2”, in which selected research outputs are verified concerning their potential application. The verification proceeds in the form of partial developmental projects nominated by researchers and confirmed by the internal IMG Commercialization Board (see the documents below).
The partial developmental projects currently implemented within the framework of the TP01010060 project (see the documents below) can be, at any time, complemented by additional suitable projects, which based on the Board‘s suggestion will be selected for co-funding from the project. For more detailed information or for direct submission of a project proposal, kindly contact us by e-mail at firstname.lastname@example.org and you will be assisted by the team of the Technology Transfer Centre.
The project TP01010060 “Applied Molecular Genetics and Biology – IMG Gamma 2” was co-financed by the state support of The Technology Agency of the Czech Republic within the programme GAMA 2.